In what is said to be the largest long-term extension dataset to date for diabetic macular oedema (DME), Roche reports that its Vabysmo® (faricimab) was well-tolerated in DME patients receiving treatment for up to 4 years. The “RHONE-X” study met all primary endpoints, with more than 90% of patients free of DME after 4 years.
Vabysmo® was first approved in the US in January 2022 for nAMD and DME and is available in multiple countries, including Europe, Canada and Australia. Vabysmo® was also approved in the US (in October 2023) and Japan (in March 2024) for macular oedema following retinal vein occlusion.